berberine has been researched along with Hyperglycemia, Postprandial in 24 studies
Hyperglycemia, Postprandial: Abnormally high BLOOD GLUCOSE level after a meal.
Excerpt | Relevance | Reference |
---|---|---|
"Berberine and Bifidobacterium have been reported to improve glucose tolerance in people with hyperglycemia or other metabolic disorders." | 9.41 | Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study. ( Ding, C; Du, Y; Fang, Y; Gao, X; He, Q; Ji, Q; Li, C; Li, S; Luo, S; Ma, K; Ming, J; Tian, Z; Wang, L; Wang, X; Wang, Z; Xie, X; Xu, X; Yang, W; Yu, X; Zhao, J, 2021) |
"Dysregulated glucagon drives hyperfunction in hepatic glucose output, which is the main cause of persistent hyperglycemia in type 2 diabetes." | 7.96 | Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice. ( Jiang, B; Jin, J; Liu, P; Sheng, L; Song, Y; Zhang, H; Zhong, Y; Zhou, H, 2020) |
"This study investigated the effects of berberine on amelioration of hyperglycemia and hyperlipidemia and the mechanism involved in high glucose and high fat diet-induced diabetic hamsters." | 7.81 | Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo. ( Jin, J; Li, L; Li, P; Liu, C; Song, Y; Wang, Z; Wu, D; Xu, N; Zheng, X, 2015) |
" The aim of the present study was to examine the protective effect of the alkaloid drug berberine against hyperglycemia-induced cellular injury and endothelial dysfunction." | 7.75 | Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. ( Huang, Y; Lam, KS; Lau, CW; Li, Y; Vanhoutte, PM; Wang, Y; Wong, WT; Xu, A; Ye, H, 2009) |
"Berberine (BBR) is a widely used anti-diabetic agent, and liver glucokinase (GK) has been reported to be involved." | 5.51 | Berberine alleviates hyperglycemia by targeting hepatic glucokinase in diabetic db/db mice. ( Dang, Y; Ji, G; Li, M; Li, Q; Yao, Z; Zhang, L; Zhou, W; Zuo, J, 2019) |
"Berberine and Bifidobacterium have been reported to improve glucose tolerance in people with hyperglycemia or other metabolic disorders." | 5.41 | Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study. ( Ding, C; Du, Y; Fang, Y; Gao, X; He, Q; Ji, Q; Li, C; Li, S; Luo, S; Ma, K; Ming, J; Tian, Z; Wang, L; Wang, X; Wang, Z; Xie, X; Xu, X; Yang, W; Yu, X; Zhao, J, 2021) |
"Dysregulated glucagon drives hyperfunction in hepatic glucose output, which is the main cause of persistent hyperglycemia in type 2 diabetes." | 3.96 | Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice. ( Jiang, B; Jin, J; Liu, P; Sheng, L; Song, Y; Zhang, H; Zhong, Y; Zhou, H, 2020) |
"This study investigated the effects of berberine on amelioration of hyperglycemia and hyperlipidemia and the mechanism involved in high glucose and high fat diet-induced diabetic hamsters." | 3.81 | Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo. ( Jin, J; Li, L; Li, P; Liu, C; Song, Y; Wang, Z; Wu, D; Xu, N; Zheng, X, 2015) |
"Berberine (BBR) has recently been shown to improve insulin sensitivity in rodent models of insulin resistance." | 3.78 | Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. ( Duarte, FV; Gomes, AP; Hubbard, BP; Jones, JG; Nunes, P; Palmeira, CM; Rolo, AP; Sinclair, DA; Teodoro, JS; Varela, AT, 2012) |
" Berberine (BBR) has recently been shown to lower blood glucose levels and to improve insulin resistance in db/db mice partly through the activation of AMP-activated protein kinase (AMPK) signaling and induction of phosphorylation of insulin receptor (IR)." | 3.76 | Berberine inhibits PTP1B activity and mimics insulin action. ( Chen, C; Huang, C; Zhang, Y, 2010) |
" The aim of the present study was to examine the protective effect of the alkaloid drug berberine against hyperglycemia-induced cellular injury and endothelial dysfunction." | 3.75 | Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. ( Huang, Y; Lam, KS; Lau, CW; Li, Y; Vanhoutte, PM; Wang, Y; Wong, WT; Xu, A; Ye, H, 2009) |
"A berberine pretreatment attenuated paliperidone-induced increases in blood concentrations of glucose, adrenaline, and insulin and phosphorylated AMPK concentrations in the hypothalamus." | 1.72 | Paliperidone-Induced Acute Hyperglycemia Is Caused by Adrenaline Secretion via the Activation of Hypothalamic AMP-Activated Protein Kinase. ( Aoyama, T; Ishiwata, Y; Kawano, Y; Nagata, M; Negishi, K; Takahashi, H; Xue, B, 2022) |
"Postprandial hyperglycemia is an important causative factor of type 2 diabetes mellitus, and permanent localization of intestinal GLUT2 in the brush border membrane is an important reason of postprandial hyperglycemia." | 1.62 | Berberine Decreases Intestinal GLUT2 Translocation and Reduces Intestinal Glucose Absorption in Mice. ( Dong, L; Li, J; Yang, E; Yang, H; Zhang, M, 2021) |
"Berberine (BBR) is a widely used anti-diabetic agent, and liver glucokinase (GK) has been reported to be involved." | 1.51 | Berberine alleviates hyperglycemia by targeting hepatic glucokinase in diabetic db/db mice. ( Dang, Y; Ji, G; Li, M; Li, Q; Yao, Z; Zhang, L; Zhou, W; Zuo, J, 2019) |
" This work intended to develop selenium-coated nanostructured lipid carriers (SeNLCs) for enhancing the oral bioavailability and the curative effect of berberine, an antidiabetic phytomedicine." | 1.46 | Selenium-coated nanostructured lipid carriers used for oral delivery of berberine to accomplish a synergic hypoglycemic effect. ( Hou, Y; Song, X; Yin, J; Yin, Y, 2017) |
"Berberine is an isoquinoline alkaloid widely used in Asian countries as a traditional medicine." | 1.38 | Possible therapeutic potential of berberine in diabetic osteopathy. ( Bhutada, PS; Kaulaskar, SV; Rahigude, AB, 2012) |
"Berberine treatment reduced the plasma sugar and lipid levels by 24-69% in the rat model of hyperglycemia and hypercholesterolemia." | 1.37 | Berberine attenuates cardiac dysfunction in hyperglycemic and hypercholesterolemic rats. ( Dong, SF; Hao, YZ; Hong, Y; Liu, M; Liu, Y; Sun, JN; Yu, HS, 2011) |
"Berberine was found to effectively inhibit the activity of disaccharidases in Caco-2 cells." | 1.32 | The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption. ( Fawcett, JP; Huang, ZJ; Liu, XD; Pan, GY; Sun, JG; Wang, GJ; Xie, YY; Zhao, XC, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (8.33) | 29.6817 |
2010's | 13 (54.17) | 24.3611 |
2020's | 9 (37.50) | 2.80 |
Authors | Studies |
---|---|
Zhao, MM | 1 |
Lu, J | 1 |
Li, S | 2 |
Wang, H | 1 |
Cao, X | 1 |
Li, Q | 2 |
Shi, TT | 1 |
Matsunaga, K | 1 |
Chen, C | 2 |
Huang, H | 2 |
Izumi, T | 1 |
Yang, JK | 1 |
Wang, N | 1 |
Wang, L | 2 |
Zhang, C | 1 |
Tan, HY | 1 |
Zhang, Y | 2 |
Feng, Y | 1 |
Zhang, M | 1 |
Yang, H | 1 |
Yang, E | 1 |
Li, J | 1 |
Dong, L | 1 |
Xue, B | 1 |
Ishiwata, Y | 1 |
Kawano, Y | 1 |
Takahashi, H | 1 |
Negishi, K | 1 |
Aoyama, T | 1 |
Nagata, M | 1 |
Purwaningsih, I | 1 |
Maksum, IP | 1 |
Sumiarsa, D | 1 |
Sriwidodo, S | 1 |
Zhong, Y | 1 |
Jin, J | 2 |
Liu, P | 2 |
Song, Y | 2 |
Zhang, H | 2 |
Sheng, L | 1 |
Zhou, H | 1 |
Jiang, B | 1 |
Li, M | 2 |
Zhou, W | 2 |
Dang, Y | 2 |
Li, C | 2 |
Ji, G | 2 |
Zhang, L | 2 |
Yin, Z | 1 |
Tan, R | 1 |
Yuan, T | 1 |
Chen, S | 1 |
Quan, Y | 1 |
Hao, Q | 1 |
Zeng, J | 1 |
Zhao, J | 2 |
Li, L | 2 |
Ming, J | 1 |
Yu, X | 1 |
Xu, X | 1 |
Ding, C | 1 |
Wang, Z | 2 |
Xie, X | 2 |
Yang, W | 1 |
Luo, S | 1 |
He, Q | 1 |
Du, Y | 1 |
Tian, Z | 1 |
Gao, X | 1 |
Ma, K | 1 |
Fang, Y | 1 |
Wang, X | 1 |
Ji, Q | 1 |
Yin, J | 1 |
Hou, Y | 1 |
Yin, Y | 1 |
Song, X | 1 |
Yue, X | 1 |
Liang, J | 1 |
Gu, F | 1 |
Du, D | 1 |
Chen, F | 1 |
Zuo, J | 1 |
Yao, Z | 1 |
Liu, C | 1 |
Wu, D | 2 |
Zheng, X | 1 |
Li, P | 1 |
Xu, N | 1 |
Ma, YG | 1 |
Zhang, YB | 1 |
Bai, YG | 1 |
Dai, ZJ | 1 |
Liang, L | 1 |
Liu, M | 2 |
Xie, MJ | 1 |
Guan, HT | 1 |
Yang, N | 1 |
Sun, RB | 1 |
Chen, XL | 1 |
Zhen, L | 1 |
Ge, C | 1 |
Zhao, YQ | 1 |
He, J | 1 |
Geng, JL | 1 |
Guo, JH | 1 |
Yu, XY | 1 |
Fei, F | 1 |
Feng, SQ | 1 |
Zhu, XX | 1 |
Wang, HB | 1 |
Fu, FH | 1 |
Aa, JY | 1 |
Wang, GJ | 2 |
Wang, Y | 1 |
Huang, Y | 1 |
Lam, KS | 1 |
Li, Y | 1 |
Wong, WT | 1 |
Ye, H | 1 |
Lau, CW | 1 |
Vanhoutte, PM | 1 |
Xu, A | 1 |
Wei, J | 1 |
Xue, R | 1 |
Wu, JD | 1 |
Zhao, W | 1 |
Wang, ZZ | 1 |
Wang, SK | 1 |
Zhou, ZX | 1 |
Song, DQ | 1 |
Wang, YM | 1 |
Pan, HN | 1 |
Kong, WJ | 1 |
Jiang, JD | 1 |
Huang, C | 1 |
Dong, SF | 1 |
Hong, Y | 1 |
Hao, YZ | 1 |
Yu, HS | 1 |
Liu, Y | 1 |
Sun, JN | 1 |
Li, W | 1 |
Lan, T | 1 |
Liu, W | 1 |
Peng, J | 1 |
Huang, K | 1 |
Huang, J | 1 |
Shen, X | 1 |
Gomes, AP | 1 |
Duarte, FV | 1 |
Nunes, P | 1 |
Hubbard, BP | 1 |
Teodoro, JS | 1 |
Varela, AT | 1 |
Jones, JG | 1 |
Sinclair, DA | 1 |
Palmeira, CM | 1 |
Rolo, AP | 1 |
Wen, W | 1 |
Qi, CL | 1 |
Zhao, RX | 1 |
Lü, JH | 1 |
Zhong, CY | 1 |
Chen, YY | 1 |
Rahigude, AB | 1 |
Kaulaskar, SV | 1 |
Bhutada, PS | 1 |
Pan, GY | 1 |
Huang, ZJ | 1 |
Fawcett, JP | 1 |
Liu, XD | 1 |
Zhao, XC | 1 |
Sun, JG | 1 |
Xie, YY | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Effect of Berberine on Insulin Release at a High Blood Glucose Level in Normal Man[NCT03972215] | Early Phase 1 | 15 participants (Actual) | Interventional | 2019-10-01 | Completed | ||
Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level: an Multicenter, Randomized, Double-blinded, Placebo-controlled Study.[NCT03330184] | 300 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for berberine and Hyperglycemia, Postprandial
Article | Year |
---|---|
A Review of
Topics: Alkaloids; Antioxidants; Berberine; Humans; Hyperglycemia; Hypoglycemic Agents; Menispermaceae | 2023 |
3 trials available for berberine and Hyperglycemia, Postprandial
Article | Year |
---|---|
Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.
Topics: Adolescent; Adult; Animals; Berberine; Cell Line, Tumor; Cross-Over Studies; Diet, High-Fat; Ether-A | 2021 |
Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study.
Topics: Aged; Berberine; Bifidobacterium; Blood Glucose; Combined Modality Therapy; Disease Management; Fece | 2021 |
Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.
Topics: Aged; Berberine; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Female; Gene Expression; Human | 2010 |
20 other studies available for berberine and Hyperglycemia, Postprandial
Article | Year |
---|---|
Berberine suppresses advanced glycation end products-associated diabetic retinopathy in hyperglycemic mice.
Topics: Animals; Berberine; Diabetic Retinopathy; Disease Models, Animal; Glycation End Products, Advanced; | 2021 |
Berberine Decreases Intestinal GLUT2 Translocation and Reduces Intestinal Glucose Absorption in Mice.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Cell Line; Diabetes Mellitus, Experimental; Epitheli | 2021 |
Paliperidone-Induced Acute Hyperglycemia Is Caused by Adrenaline Secretion via the Activation of Hypothalamic AMP-Activated Protein Kinase.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Glucose; Hyperglycemia; Hypothalamus; Insulin; Pa | 2022 |
Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Glucagon; Hyperglycemia; Liver; Mice; Mice, Obe | 2020 |
Berberine compounds improves hyperglycemia via microbiome mediated colonic TGR5-GLP pathway in db/db mice.
Topics: Animals; Berberine; Colon; Gastrointestinal Microbiome; Glucagon-Like Peptides; Hyperglycemia; Male; | 2020 |
Berberine prevents diabetic retinopathy through inhibiting HIF-1α /VEGF/ NF-κ B pathway in db/db mice.
Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Hyperglyce | 2021 |
Selenium-coated nanostructured lipid carriers used for oral delivery of berberine to accomplish a synergic hypoglycemic effect.
Topics: Administration, Oral; Animals; Berberine; Biological Availability; Caco-2 Cells; Delayed-Action Prep | 2017 |
Berberine activates bitter taste responses of enteroendocrine STC-1 cells.
Topics: Berberine; Cell Line, Tumor; Enteroendocrine Cells; Estrenes; Glucagon-Like Peptide 1; Humans; Hyper | 2018 |
Berberine alleviates hyperglycemia by targeting hepatic glucokinase in diabetic db/db mice.
Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Glucokinase; Glucose; Hepatocytes; Hum | 2019 |
Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo.
Topics: Animals; Berberine; Blood Glucose; Cardiovascular Diseases; Cricetinae; Diabetes Mellitus, Experimen | 2015 |
Berberine alleviates the cerebrovascular contractility in streptozotocin-induced diabetic rats through modulation of intracellular Ca²⁺ handling in smooth muscle cells.
Topics: Animals; Berberine; Blood Glucose; Calcium; Calcium Channels, L-Type; Diabetes Mellitus, Experimenta | 2016 |
In vitro assessment of the glucose-lowering effects of berberrubine-9-O-β-D-glucuronide, an active metabolite of berberrubine.
Topics: Animals; Berberine; Glucuronides; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Mice, Inbred C57 | 2017 |
Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase.
Topics: AMP-Activated Protein Kinases; Animals; Aorta; Apoptosis; Berberine; Cell Adhesion; Cell Line; Endot | 2009 |
Berberine inhibits PTP1B activity and mimics insulin action.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Berberine; Diet; Female; Hyperglycemia; Hypoglycemic Agents; Insu | 2010 |
Berberine attenuates cardiac dysfunction in hyperglycemic and hypercholesterolemic rats.
Topics: Animals; Berberine; Biomarkers; Dietary Fats; Gene Expression Regulation; Glucose Transporter Type 4 | 2011 |
Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway.
Topics: Animals; Berberine; Blood Glucose; Blotting, Western; Diabetes Mellitus, Experimental; Glucokinase; | 2011 |
Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Cell Line; Diet, High-Fat; Glucose; Hormones; Hyp | 2012 |
Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Cholesterol; Creatinine; Diabetes Mellitus, Experime | 2012 |
Possible therapeutic potential of berberine in diabetic osteopathy.
Topics: Berberine; Calcitonin; Diabetes Complications; Glucagon-Like Peptides; Glycation End Products, Advan | 2012 |
The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption.
Topics: alpha-Glucosidases; Berberine; Caco-2 Cells; Enzyme Activation; Enzyme Inhibitors; Gluconeogenesis; | 2003 |